SSY Group Secures Hebei Regulatory Approval for Full-Range CRP and SAA/CRP Diagnostic Test Kits

Bulletin Express05-06

SSY Group Limited announced on 6 May 2026 that its Full-range C-reactive protein (hsCRP + conventional CRP) Test Kit and Serum Amyloid A / C-reactive protein (SAA/CRP) Test Kit have received medical device registration certificates from the Hebei Provincial Drug Administration of China.

The Full-range CRP Test Kit, based on fluorescent immunochromatography, enables in-vitro quantitative detection of C-reactive protein levels in whole blood, serum and plasma, supporting clinical diagnosis of non-specific inflammation and cardiovascular diseases.

The SAA/CRP Test Kit, also employing fluorescent immunochromatography, quantitatively measures serum amyloid A and C-reactive protein in human serum, plasma or whole blood, and is intended as an adjunct diagnostic tool for non-specific inflammation.

Management highlighted that successive approvals of multiple test kits have opened a new pathway for the Group’s medical device product line.

The announcement was released as a voluntary update to inform shareholders and potential investors of the latest product development progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174382331?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174382331","market":"us","top_or_hot":-1,"title":"SSY Group Secures Hebei Regulatory Approval for Full-Range CRP and SAA/CRP Diagnostic Test Kits","media":"Bulletin Express","content":"<p>SSY Group Limited announced on 6 May 2026 that its Full-range C-reactive protein (hsCRP + conventional CRP) Test Kit and Serum Amyloid A / C-reactive protein (SAA/CRP) Test Kit have received medical device registration certificates from the Hebei Provincial Drug Administration of China.</p>\n<p>The Full-range CRP Test Kit, based on fluorescent immunochromatography, enables in-vitro quantitative detection of C-reactive protein levels in whole blood, serum and plasma, supporting clinical diagnosis of non-specific inflammation and cardiovascular diseases.</p>\n<p>The SAA/CRP Test Kit, also employing fluorescent immunochromatography, quantitatively measures serum amyloid A and C-reactive protein in human serum, plasma or whole blood, and is intended as an adjunct diagnostic tool for non-specific inflammation.</p>\n<p>Management highlighted that successive approvals of multiple test kits have opened a new pathway for the Group’s medical device product line.</p>\n<p>The announcement was released as a voluntary update to inform shareholders and potential investors of the latest product development progress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Secures Hebei Regulatory Approval for Full-Range CRP and SAA/CRP Diagnostic Test Kits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Secures Hebei Regulatory Approval for Full-Range CRP and SAA/CRP Diagnostic Test Kits\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY Group Limited announced on 6 May 2026 that its Full-range C-reactive protein (hsCRP + conventional CRP) Test Kit and Serum Amyloid A / C-reactive protein (SAA/CRP) Test Kit have received medical device registration certificates from the Hebei Provincial Drug Administration of China.</p>\n<p>The Full-range CRP Test Kit, based on fluorescent immunochromatography, enables in-vitro quantitative detection of C-reactive protein levels in whole blood, serum and plasma, supporting clinical diagnosis of non-specific inflammation and cardiovascular diseases.</p>\n<p>The SAA/CRP Test Kit, also employing fluorescent immunochromatography, quantitatively measures serum amyloid A and C-reactive protein in human serum, plasma or whole blood, and is intended as an adjunct diagnostic tool for non-specific inflammation.</p>\n<p>Management highlighted that successive approvals of multiple test kits have opened a new pathway for the Group’s medical device product line.</p>\n<p>The announcement was released as a voluntary update to inform shareholders and potential investors of the latest product development progress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"","article_id":"1174382331","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174382331","pubTimestamp":1778058196,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"SSY Group Limited announced on 6 May 2026 that its Full-range C-reactive protein (hsCRP + conventional CRP) Test Kit and Serum Amyloid A / C-reactive protein (SAA/CRP) Test Kit have received medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02005":"石四药集团"},"translate_title":"SSY集团全系列CRP和SAA/CRP诊断检测试剂盒获得河北监管批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY Group Limited announced on 6 May 2026 that its Full-range C-reactive protein (hsCRP + conventional CRP) Test Kit and Serum Amyloid A / C-reactive protein (SAA/CRP) Test Kit have received medical device registration certificates from the Hebei Provincial Drug Administration of China.\nThe Full-range CRP Test Kit, based on fluorescent immunochromatography, enables in-vitro quantitative detection of C-reactive protein levels in whole blood, serum and plasma, supporting clinical diagnosis of non-specific inflammation and cardiovascular diseases.\nThe SAA/CRP Test Kit, also employing fluorescent immunochromatography, quantitatively measures serum amyloid A and C-reactive protein in human serum, plasma or whole blood, and is intended as an adjunct diagnostic tool for non-specific inflammation.\nManagement highlighted that successive approvals of multiple test kits have opened a new pathway for the Group’s medical device product line.\nThe announcement was released as a voluntary update to inform shareholders and potential investors of the latest product development progress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174382331","isCrawlerRequest":true}